



4410/C
Ward
60-7-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Stewart D. Lyman and M. Patricia Beckmann

Attorney Docket No.: 28131

Serial No.: 08/994,468

Technology Center: 1633

Filed: December 19, 1997

Examiner: J. Kerr

CPA Filed: May 26, 2000

For: MEDIUM CONTAINING FLT3 LIGAND FOR
CULTURING HEMATOPOIETIC CELLS

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.56(d)

Box CPA
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated February 29, 2000 (Paper No. 10), and pursuant to Rule 111 of the Rules of Practice, Applicants offer the following remarks and proposed amendments: Reconsideration of the above-captioned application is respectfully requested. Enclosed please find a request for a request for a Continued Prosecution Application, including the appropriate fee, and an article by Anderson, W.F. published in Science 288:627-629 (2000) [attached as "Exhibit A" to Amendment].

Amendments

In the claims:

Please amend the claims as follows.

Sub E

1. (amended) A hematopoietic cell expansion media comprising cell growth media[,] and flt3-L [alone or in combination with a cellular growth factor], wherein the flt3-L [and the growth factor are] is in an amount sufficient to cause hematopoietic cell expansion.

Sub D

2. (amended) A method for expanding hematopoietic cells comprising contacting the cells with flt3-L [alone or in combination with a cellular growth factor], wherein the flt3-L [and the growth factor are] is in an amount sufficient to cause hematopoietic cell expansion.
